Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
FlashNews:
From Childhood Trauma to Purpose: Marion Welch Unveils “One Decision at a Time”
Marion Welch Releases One Decision at a Time, a Memoir on Building Resilience Through Deliberate Choice
Everion Pharmaceuticals Appoints Multilingual International Executive Alina Khomenko as Chief Operating Officer
Wenjin to Present Market-Specific Helmet Development and OEM Solutions at EICMA 2026
Space: the final frontline
Solana Foundation hires ex-Binance CMO and payments exec as new partnerships expand
Private Equity Firm Inflexion Invests in Manucurist
Global bond sell-off spreads as oil climbs back to $105
Do any coffee-flavoured drinks come close to the real thing?
HIFI raises $37M to expand stablecoin payments, tokenized markets
What Does Italian Beauty Have To Prove?
‘Going places with panache’: Max Mara channels audacious women for Milan show
Bose Ultra Open Earbuds Are $100 Off Right Now
An OpenAI Agent Hacked Australia’s Health Service. Their Government Found Out Months Later
Vietnam Airlines Partners with Visa and AWS to Advance Digital Transformation and AI
Finnair strengthens its Japan network and will operate up to three daily flights to Tokyo next summe
Teen rocker Nene Royal becomes first Thai to win America’s Got Talent
Harry Potter play producer says cost of living made two-part show ‘impossible’
A Journey Through Laughter, Loss, and Resilience – Eric Noriega Debuts Mi Grandulon: Poetry and Short
Home » Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.